Scisparc advances its phase iib clinical trial in patients with tourette syndrome with its proprietary drug candidate sci-110

Tel aviv, israel, jan. 18, 2022 /prnewswire/ -- scisparc ltd. (nasdaq: sprc), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "company" or "scisparc"), today announced that it has entered into an agreement with two clinical sites: hannover medical school in hannover, germany, and tel-aviv sourasky medical school, in tel-aviv, israel, to further its phase iib clinical study for sci-110, the company's proprietary drug candidate, for patients suffering from tourette syndrome (the "study" or the "trial").
SPRC Ratings Summary
SPRC Quant Ranking